M&A Deal Summary

Alcoa Acquires Gentek Building Products

On March 8, 2001, Alcoa acquired building materials company Gentek Building Products from Genstar Capital

Acquisition Highlights
  • This is Alcoa’s 2nd transaction in the Building Materials sector.
  • This is Alcoa’s 1st transaction in Canada.
  • This is Alcoa’s 1st transaction in Ontario.

M&A Deal Summary

Date 2001-03-08
Target Gentek Building Products
Sector Building Materials
Buyer(s) Alcoa
Sellers(s) Genstar Capital
Deal Type Add-on Acquisition

Target

Gentek Building Products

Concord, Ontario, Canada
Gentek Building Products, Inc. is a North American manufacturer and distributor of exterior building products for residential renovation and new construction and engineered metal buildings for agricultural and commercial markets.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alcoa

Pittsburgh, Pennsylvania, United States

Category Company
Founded 1886
Sector Metals/Mining
Employees13,600
Revenue 10.6B USD (2023)
DESCRIPTION

Alcoa is a lightweight metals engineering and manufacturing company. Alcoa’s multi-material products, which include aluminum, titanium, and nickel, are used worldwide in aircraft, automobiles, commercial transportation, packaging, building and construction, oil and gas, defense, consumer electronics, and industrial applications. Alcoa was incorporated in 1886 and is based in Pittsburgh, Pennsylvania.


DEAL STATS #
Overall 9 of 24
Sector (Building Materials) 2 of 3
Type (Add-on Acquisition) 7 of 18
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2001) 2 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2001-03-08 Gentek Holdings

Cuyahoga Falls, Ohio, United States

Gentek Holdings is a manufacturer and distributor of residential aluminum siding into a world class manufacturer and distributor of vinyl siding.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2001-04-11 Aluminium Oxid Stade

Stade,, Germany

Aluminium Oxid Stade GmbH owns and operates an alumina refinery that produces alumina, and dried and wet aluminum hydroxide.

Sell -

Seller(S) 1

SELLER

Genstar Capital

San Francisco, California, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1988
PE ASSETS 49.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Genstar Capital is a private equity firm that seeks investments in life science, healthcare, medical products, industrial technology, software, financial services, packaging, building materials, manufacturing, and business services companies. Genstar looks to invest between $50 and $400 million of equity capital in businesses valued up to $1 billion. Target transaction situations include control-oriented leveraged buyouts of corporate divisions, privately held businesses or public companies, minority investments in privately held businesses or public companies, ownership restructurings/recapitalizations of privately held businesses, growth equity financings, partnerships with other strategic or financial buyers, and take privates. Genstar Capital was formed in 1988 and is based in San Francisco, California.


DEAL STATS #
Overall 4 of 60
Sector (Building Materials) 2 of 4
Type (Add-on Acquisition) 2 of 18
State (Ontario) 1 of 3
Country (Canada) 1 of 6
Year (2001) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-06-12 NEN Life Sciences

Boston, Massachusetts, United States

NEN Life Sciences, Inc. is a provider of high value research consumables and technology-based tools to the life science industry. Company provide radioisotopically labeled biochemicals primarily for use in pharmaceutical, academic and government life science research.

Sell $400M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2001-07-09 PRA Health Sciences

Raleigh, North Carolina, United States

PRA Health Sciences, Inc. is an international clinical research organization. PRA provides services on a contract basis to the pharmaceutical and biotechnology industries. Comprehensive services include the filing of Investigational New Drug (IND) and similar regulatory applications, management and implementation of Phase I through IV clinical trials, preparation and submission of New Drug Applications (NDAs), and post-marketing surveillance on an international basis. PRA was formed in 1976 and is based in Raleigh, North Carolina.

Buy -